勃林格殷格翰-话题@MedSci

#勃林格殷格翰#

67篇内容 | 2580人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1447212, encodeId=2632144e2124d, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=FDA：勃林格殷格翰抗癌药afatinib LUX-Lung临床项目硕果累累, objectType=article, longId=22562, objectId=95f622562aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95f622562aa, replyNumber=0, likeNumber=65, createdTime=2013-08-04, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95f622562aa, moduleTitle=FDA：勃林格殷格翰抗癌药afatinib LUX-Lung临床项目硕果累累, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95f622562aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447211, encodeId=db84144e2113d, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=FDA：勃林格殷格翰和礼来启动Linagliptin上市后试验CARMELINA1, objectType=article, longId=22561, objectId=ea712256171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea712256171, replyNumber=0, likeNumber=58, createdTime=2013-08-04, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea712256171, moduleTitle=FDA：勃林格殷格翰和礼来启动Linagliptin上市后试验CARMELINA1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea712256171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447210, encodeId=0cbc144e21051, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰afatinib获CHMP积极意见, objectType=article, longId=22425, objectId=467622425e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=467622425e9, replyNumber=0, likeNumber=76, createdTime=2013-08-02, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=467622425e9, moduleTitle=勃林格殷格翰afatinib获CHMP积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=467622425e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447209, encodeId=cc7f144e209b5, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=FDA：勃林格殷格翰用于NSCLC药物afatinib获FDA批准, objectType=article, longId=21574, objectId=e6e7215e4e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6e7215e4e2, replyNumber=0, likeNumber=75, createdTime=2013-07-19, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6e7215e4e2, moduleTitle=FDA：勃林格殷格翰用于NSCLC药物afatinib获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6e7215e4e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447208, encodeId=9193144e2087c, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=FDA批准勃林格殷格翰旗下阿法替尼用于EGFR基因突变晚期NSCLC治疗, objectType=article, longId=21404, objectId=a78921404a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a78921404a7, replyNumber=0, likeNumber=74, createdTime=2013-07-17, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a78921404a7, moduleTitle=FDA批准勃林格殷格翰旗下阿法替尼用于EGFR基因突变晚期NSCLC治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a78921404a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447207, encodeId=6402144e20750, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰与礼来建立糖尿病联盟, objectType=article, longId=13005, objectId=c04b1300589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c04b1300589, replyNumber=0, likeNumber=73, createdTime=2012-12-16, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c04b1300589, moduleTitle=勃林格殷格翰与礼来建立糖尿病联盟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c04b1300589)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447206, encodeId=635c144e2067c, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰COPD药物olodaterol II期研究取得积极结果, objectType=article, longId=6482, objectId=d815648236, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d815648236, replyNumber=0, likeNumber=81, createdTime=2012-05-26, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d815648236, moduleTitle=勃林格殷格翰COPD药物olodaterol II期研究取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d815648236)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

勃林格殷格翰

2020-05-29

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

FDA：勃林格殷格翰抗癌药afatinib LUX-Lung临床项目硕果累累

2013-08-04

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

FDA：勃林格殷格翰和礼来启动Linagliptin上市后试验CARMELINA1

2013-08-04

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰afatinib获CHMP积极意见

2013-08-02

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

FDA：勃林格殷格翰用于NSCLC药物afatinib获FDA批准

2013-07-19

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

FDA批准勃林格殷格翰旗下阿法替尼用于EGFR基因突变晚期NSCLC治疗

2013-07-17

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰与礼来建立糖尿病联盟

2012-12-16

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰COPD药物olodaterol II期研究取得积极结果

2012-05-26

科室
- - 订阅+
  - 更多科室
工具
服务